FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Apotex Guanfacine Extended-Release Tablets 2 mg Recall

Guanfacine Extended-Release Tablets 2 mg,100-count bottles, Rx Only, Manufactured by: A…

Apotex Corp. · Weston, FL

Risk level
Class II
Reported by FDA
Apr 14, 2021
Recall ID
D-0324-2021
Check your lot numberHow we source this data

Summary

Apotex recalled Guanfacine Extended-Release Tablets 2 mg starting Mar 31, 2021. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0324-2021 on Apr 14, 2021. Reason: Cross Contamination with Other Product: Product is being recalled due to Trace Amounts of Quetiapine Fumarate. Status: Ongoing.

Why it was recalled

Cross Contamination with Other Product: Product is being recalled due to Trace Amounts of Quetiapine Fumarate

Product description

Guanfacine Extended-Release Tablets 2 mg,100-count bottles, Rx Only, Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326, NDC 60505-3928-1, UPC 3 60505 39281 0

Lot numbers, UPCs & expiration codes

Lot #: RX1662, RX1663, RX1664 Exp. 11/2022

Where it was sold

Nationwide within the United States

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0324-2021
Classification
Class II
Status
Ongoing
Recall initiated
Mar 31, 2021
FDA report date
Apr 14, 2021
Quantity
55620 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Apotex Corp.

Original FDA data

Every field from FDA enforcement report D-0324-2021, exactly as published.

Show all FDA fields
City
Weston
State
FL
Status
Ongoing
Country
United States
Event ID
87648
Address
2400 N Commerce Pkwy Ste 400
Code information
Lot #: RX1662, RX1663, RX1664 Exp. 11/2022
Postal code
33326-3253
Report date
Apr 14, 2021
Product type
Drugs
Recall number
D-0324-2021
Classification
Class II
Recalling firm
Apotex Corp.
Product quantity
55620 bottles
Reason for recall
Cross Contamination with Other Product: Product is being recalled due to Trace Amounts of Quetiapine Fumarate
Voluntary / mandated
Voluntary: Firm initiated
Product description
Guanfacine Extended-Release Tablets 2 mg,100-count bottles, Rx Only, Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326, NDC 60505-3928-1, UPC 3 60505 39281 0
Distribution pattern
Nationwide within the United States
Recall initiation date
Mar 31, 2021
Initial firm notification
Press Release
Center classification date
Apr 6, 2021

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0324-2021, published Apr 14, 2021. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls